Works by Zeng, Baozhen


Results: 20
    1
    2
    3
    4
    5

    CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma.

    Published in:
    Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.607362
    By:
    • Xue, YuanBo;
    • Lai, Xun;
    • Li, RuiLei;
    • Ge, ChunLei;
    • Zeng, BaoZhen;
    • Li, Zhen;
    • Fu, QiaoFen;
    • Zhao, LiuFang;
    • Dong, SuWei;
    • Yang, JinYan;
    • Guo, JiYin;
    • Meng, QingYin;
    • Tan, QingHua;
    • Li, ZhenHui;
    • Ding, HaiYan;
    • Zhang, YanLei;
    • Liu, ShaoHui;
    • Chang, Alex H.;
    • Yao, Hong;
    • Luo, RongCheng
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20